ZYZheng Yu

Zheng Yu

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Zheng Yu has a total of 11 co-authors. Here are the top co-authors by number of shared publications:

  • Abigail Winder

    Department of Obstetrics and Gynecology, Cardinal Bernardin Cancer Center, Loyola University Chicago, 2160 South First Avenue, Maywood, IL 60153, USA

    1 shared publication
  • Cheryl M. Czerlanis

    Division of Hematology, Oncology and Palliative Care, UW School of Medicine and Public Health, University of Wisconsin (UW) Carbone Cancer Center, 600 N. Highland Avenue, K4/530, Madison, WI 53792, USA

    1 shared publication
  • Diane Palmer

    Cancer Clinical Trials Office, Cardinal Bernardin Cancer Center, Loyola University Chicago, 2160 South First Avenue, Maywood, IL 60153, USA

    1 shared publication
  • Jennifer Guevara

    Cancer Clinical Trials Office, Cardinal Bernardin Cancer Center, Loyola University Chicago, 2160 South First Avenue, Maywood, IL 60153, USA

    1 shared publication
  • Lori Pease

    Cellular Therapy Center, Cardinal Bernardin Cancer Center, Loyola University Medical Center, 2160 South First Avenue, Maywood, IL 60153, USA

    1 shared publication
  • Margaret Liotta

    Department of Obstetrics and Gynecology, Cardinal Bernardin Cancer Center, Loyola University Chicago, 2160 South First Avenue, Maywood, IL 60153, USA

    1 shared publication

Latest Publications

  • Open Access

    Outcomes of an Alpha-DC-1 Dendritic Cell-Based Vaccine Clinical Trial in Patients with Low-Tumor-Burden High-Risk Ovarian Carcinoma

    by Patrick J. Stiff, Cheryl M. Czerlanis, Ronald K. Potkul, Margaret Liotta, Zheng Yu, Lori Pease, Swarnali Banerjee, Swati Mehrotra, Abigail Winder, Jennifer Guevara, et al.

    Background/Objectives: High-grade serous ovarian cancer (HGSOC) is usually discovered in advanced stages and often relapses shortly after initial conventional therapy. Survival in HGSOC patients might be improved with the use of novel immune therapies, which potentiate autologous anti-tumor responses. Dendritic cells (DCs) are potent antigen-presenting cells that can initiate immune responses, activate cytotoxic T cells and drive T-cell differentiation. This pilot trial evaluated the safety and efficacy of a unique DC vaccine (α-DC-1) in relapsed, advanced HGSOC patients with minimal tumor burden. Methods: Monocytes from patient leukaphereses were used to propagate a unique autologous DC, the α-DC-1, generated with granulocyte–macrophage colony-stimulating factor and interleukin-4, pulsed with keyhole limpet hemocyanin (KLH) and tumor lysate (from debulking surgery) on day 5, and matured with a cocktail of cytokines and chemokines on day 6. Mature α-DC-1 were harvested on day 7 and administered intranodally (inguinal nodes) every other week for three doses/cycle for up to three DC vaccine cycles (nine vaccines). The primary endpoints were progression-free survival (PFS) and overall survival (OS). Results: In 19 patients treated, the median PFS was 9.7 months (95% CI: (5, NA)) and the median OS was 42.2 months (95% CI: (31.2, 68.3)). In 5/19 (26.3%) patients, OS exceeded five years. Administration of six or more vaccines was associated with a significant improvement in PFS. No grade 2 or higher toxicities were noted. Conclusions: Our α-DC-1 vaccine was safe, and 94.2% elicited an immune response to KLH. The long OS, exceeding 5 years in some patients, suggests this DC vaccine may improve survival for some with relapsed HGSOC.